Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston from September 9-10, 2024. Dr. Gwenn M. Hansen, the company's chief scientific officer, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform on Tuesday, September 10, from 9:05 to 9:25 a.m. ET.
The presentation, titled 'Targeted Protein Degraders As Next Generation Antibody Payloads', will showcase Nurix's innovative approach to developing targeted protein modulation drugs for cancer and inflammatory diseases. Interested parties can access the presentation slides from September 9, 2024, through the Investors section of the Nurix website under Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, NRIX declined 4.54%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix’s Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024.
Title: Targeted Protein Degraders As Next Generation Antibody Payloads
Conference: ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Date and time: Tuesday, September 10, 9:05 – 9:25 a.m. ET
The slides for this presentation may be accessed beginning on September 9, 2024, via a link in the Investors section of the Nurix website under Events and Presentations.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When and where is Nurix Therapeutics presenting at the ADC & Radiopharmaceuticals Summit?
What is the topic of Nurix Therapeutics' presentation at the 2024 ADC Summit?
Who will be presenting for Nurix Therapeutics at the September 2024 ADC Summit?
How can investors access Nurix Therapeutics' presentation slides from the 2024 ADC Summit?
What is the main focus of Nurix Therapeutics' drug development?
